These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 560884)

  • 1. Lithium inhibition of norepinephrine and dopamine receptors.
    Flemenbaum A
    Biol Psychiatry; 1977 Aug; 12(4):563-72. PubMed ID: 560884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic lithium treatment and dopamine-mediated behavior.
    Ebstein RP; Eliashar S; Belmaker RH; Ben-Uriah Y; Yehuda S
    Biol Psychiatry; 1980 Jun; 15(3):459-67. PubMed ID: 7189675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
    Meltzer LT; Caprathe BW; Christoffersen CL; Corbin AE; Jaen JC; Ninteman FW; Pugsley TA; Serpa KA; Shih YH; Whetzel SZ
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1177-89. PubMed ID: 8103791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of chronic dietary lithium on behavioral indices of dopamine denervation supersensitivity in the rat.
    Swerdlow NR; Lee D; Koob GF; Vaccarino FJ
    J Pharmacol Exp Ther; 1985 Nov; 235(2):324-9. PubMed ID: 3932641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
    Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats].
    Minematsu N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Jun; 15(3):247-52. PubMed ID: 7584718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of neurochemical changes in dopamine systems after repeated cocaine administration.
    Peris J; Boyson SJ; Cass WA; Curella P; Dwoskin LP; Larson G; Lin LH; Yasuda RP; Zahniser NR
    J Pharmacol Exp Ther; 1990 Apr; 253(1):38-44. PubMed ID: 2329520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD; Harting J; Minck KO
    J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between agents stimulating and inhibiting the central dopamine receptors and octopamine.
    Jagiełło-Wójtowicz
    Acta Physiol Pol; 1980; 31(2):153-8. PubMed ID: 6771963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of baclofen and aminooxyacetic acid on the action of drugs stimulating the dopaminergic system.
    Sypniewska M
    Pol J Pharmacol Pharm; 1978; 30(6):755-66. PubMed ID: 573471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between self-administration of amphetamine and monoamine receptors in brain: comparison with cocaine.
    Ritz MC; Kuhar MJ
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1010-7. PubMed ID: 2703961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the participation of the dopaminergic system in the central effects of chelidonine.
    Kleinrok Z; Szponar J; Matuszek B; Jagiełło-Wójtowicz E
    Pol J Pharmacol Pharm; 1990; 42(5):417-24. PubMed ID: 2098751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in locomotor activity during chronic cocaine administration: effect on dopamine receptors and interaction with opioids.
    Kunko PM; French D; Izenwasser S
    J Pharmacol Exp Ther; 1998 Apr; 285(1):277-84. PubMed ID: 9536022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of behavioral effects of cocaine by lithium.
    Flemenbaum A
    Pharmacol Biochem Behav; 1977 Jul; 7(1):83-5. PubMed ID: 561966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central antiserotonergic and antidopaminergic action of pirenperone, a putative 5-HT2 receptor antagonist.
    Pawłowski L; Siwanowicz J; Bigajska K; Przegaliński E
    Pol J Pharmacol Pharm; 1985; 37(2):179-96. PubMed ID: 4048012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies.
    Broderick PA; Olabisi OA; Rahni DN; Zhou Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):547-57. PubMed ID: 15093963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.
    Niemegeers CJ; Lenaerts FM; Artois KS; Janssen PA
    Arch Int Pharmacodyn Ther; 1977 Jun; 227(2):238-53. PubMed ID: 20857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.